Edition:
United States

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

21.92USD
19 Jan 2018
Change (% chg)

$0.99 (+4.73%)
Prev Close
$20.93
Open
$21.11
Day's High
$22.34
Day's Low
$20.81
Volume
425,499
Avg. Vol
364,396
52-wk High
$23.71
52-wk Low
$8.14

Latest Key Developments (Source: Significant Developments)

PTC Therapeutics reports qtrly net loss per share basic and diluted of $0.82
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Ptc Therapeutics Inc ::Qtrly total revenues $41.9 million versus $22.98 million.Qtrly net loss per share basic and diluted $0.82.Q3 earnings per share view $-0.68, revenue view $42.2 million -- Thomson Reuters I/B/E/S.Increasing 2017 revenue guidance to $160-$185M​.FY2017 revenue view $173.4 million -- Thomson Reuters I/B/E/S.  Full Article

PTC THERAPEUTICS ANNOUNCES DATA FROM PART 1 OF SUNFISH TRIAL
Tuesday, 3 Oct 2017 10:12am EDT 

Oct 3 (Reuters) - PTC Therapeutics Inc ::RG7916 INCREASED SMN PROTEIN PRODUCTION IN SUNFISH CLINICAL TRIAL IN PATIENTS WITH TYPE 2/3 SPINAL MUSCULAR ATROPHY.PTC THERAPEUTICS INC - RG7916 REMAINS WELL-TOLERATED IN PATIENTS AT ALL DOSES AND THERE HAVE BEEN NO DRUG-RELATED SAFETY FINDINGS LEADING TO WITHDRAWAL​.PTC THERAPEUTICS INC SAYS ANNOUNCED DATA FROM PART 1 OF SUNFISH TRIAL OF RG7916 IN TYPE 2/3 SPINAL MUSCULAR ATROPHY PATIENTS​.  Full Article

PTC Therapeutics files for potential mixed shelf; size not disclosed - SEC filing‍​
Thursday, 24 Aug 2017 06:07pm EDT 

Aug 24 (Reuters) - Ptc Therapeutics Inc :Files for potential mixed shelf; size not disclosed - SEC filing‍​.  Full Article

PTC Therapeutics qtrly loss per share $0.44
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Ptc Therapeutics Inc :Ptc therapeutics - qtrly total revenues $48 million versus $15.6 million; qtrly loss per share $0.44; sees fy translarna net sales $120 million - $140 million ‍​.Q2 earnings per share view $-1.28, revenue view $28.8 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $142.2 million -- Thomson Reuters I/B/E/S.  Full Article

Great Point Partners Llc reports 5.24 percent passive stake in PTC Therapeutics Inc
Friday, 16 Jun 2017 04:09pm EDT 

June 16 (Reuters) - Great Point Partners lLC::Great Point Partners LLC reports 5.24 percent passive stake in PTC Therapeutics Inc <<>> as of June 6, 2017 .  Full Article

PTC enters into credit and security agreement for senior secured term loan facility
Monday, 8 May 2017 07:44am EDT 

May 8 (Reuters) - Ptc Therapeutics Inc :Ptc therapeutics inc- on may 5, entered into a credit and security agreement for a senior secured term loan facility of $60.0 million - sec filing.Ptc therapeutics inc- final maturity date under credit agreement is may 1, 2021.Ptc therapeutics inc - on loan facility of $60.0 million, $40.0 million was drawn by company on may 5, 2017.Ptc therapeutics-$20.0 million under facility available upon co's demonstration, on/prior to dec 31, 2018, of net product revenue equaling/exceeding $120 million.  Full Article

PTC Therapeutics qtrly loss per share $0.85
Monday, 8 May 2017 07:30am EDT 

May 8 (Reuters) - PTC Therapeutics Inc : :Qtrly loss per share $0.85.Qtrly total revenues $26,5 million versus $18.9 million.PTC Therapeutics Inc - translarna net sales for 2017 are now anticipated to be between $115 and $130 million.PTC Therapeutics Inc -GAAP operating expenses for full year 2017 are anticipated to be between $250 to $260 million.  Full Article

Complete Pharma reports 16.2 pct passive stake in PTC Therapeutics
Thursday, 27 Apr 2017 06:08pm EDT 

April 27 (Reuters) - Ptc Therapeutics Inc :Complete Pharma Holdings II LLC reports 16.2 percent passive stake in PTC Therapeutics Inc as on April 20, 2017 - SEC filing.  Full Article

PTC Therapeutics reports departure of CFO
Monday, 10 Apr 2017 04:01pm EDT 

PTC Therapeutics Inc : PTC Therapeutics announces departure of chief financial officer, Shane Kovacs . PTC Therapeutics Inc says PTC has initiated a search process to appoint a new CFO .PTC Therapeutics - Shane is expected to remain with PTC through closing of PTC's pending acquisition of all rights to emflaza from Marathon Pharma.  Full Article

PTC says they "plan to re-examine the price of Emflaza": Conf Call
Thursday, 16 Mar 2017 08:00am EDT 

PTC Therapeutics Inc : PTC says prior to FDA approval, access to Emflaza has been limited to small number of patients, "We aim to close this gap with the launch": Conf Call . PTC says deal will diversify its business, enabling revenue generation through 2 products, & expanding commercial geographic footprint to include us: Conf Call . PTC says they "plan to re-examine the price of Emflaza": Conf Call . PTC says Emflaza launch would enable it to establish a complete U.S medical sales and marketing footprint ahead of a potential Translarna launch : Conf Call . PTC says anticipate an increase in operating expenses in 2017 : Conf Call . PTC says Emflaza sales are expected to begin later this year : Conf Call . PTC says "we appreciate that pricing is receiving a lot of attention and we believe that a change needs to be made": Conf Call . PTC says "ensuring access to the drug (Emflaza) is a priority and until recently only a small fraction of patients had access": Conf Call . PTC says it's "premature" to comment on exactly what that price level (for Emflaza) is going to be at this time: Conf Call . PTC "we'll think about updating our guidance in terms of operating expenses probably on our Q1 call as we close the (Emflaza) launch & finalize plan: Conf Call . PTC says "really prior to this approval there is really less than 10 percent of patients that were able to get Emflaza": Conf Call.  Full Article

FDA declines to approve PTC's Duchenne drug

The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works.